期刊文献+

血清人附睾蛋白4对卵巢上皮性癌的诊断价值 被引量:17

The diagnostic values of serum HE4 levels in epithelial ovarian carcinoma
原文传递
导出
摘要 目的探讨血清人附睾蛋白4(HE4)对卵巢上皮性癌的诊断价值。方法 2007年12月至2008年12月在河北医科大学第二医院采用酶联免疫吸附试验,检测血清HE4在健康妇女、卵巢良性上皮性肿瘤、卵巢交界性肿瘤及卵巢癌患者血清中的水平。分析血清HE4诊断卵巢上皮性癌的价值。结果在健康妇女、卵巢良性上皮性肿瘤、卵巢交界性肿瘤及卵巢癌患者术前血清中,HE4的中位数分别为41.10、43.98、65.21、260.90pmol/L;HE4在术前卵巢癌组表达水平均高于前3组,差异均有统计学意义(P<0.05),前3组比较差异均无统计学意义;卵巢癌患者术后血清中HE4的中位数为124.32pmol/L,术前血清水平明显高于术后血清水平(P<0.05)。卵巢癌患者术前血清HE4质量浓度与病理类型、血清CA125质量浓度相关。以健康妇女组+良性肿瘤组为参照人群,HE4检测卵巢癌的ROC-AUC为0.960,HE4质量浓度在107.15pmol/L时,其ROC曲线(敏感性+特异性)-1的差值最大,即为最佳界值点。HE4的界值点为107.15pmol/L或150pmol/L时,HE4、CA125单项检测卵巢癌的敏感性差异无统计学意义;CA125单项检测的敏感性低于HE4+CA125联合检测的敏感性,差异有统计学意义(P<0.05);HE4单项检测的敏感性不低于上述联合检测的敏感性(P>0.05)。结论血清HE4水平可能成为卵巢癌的肿瘤标志物,其与CA125联合检测可提高卵巢癌的诊断率。 Objective To explore the diagnostic values of serum Human Epididymis Protein 4 (HE4)levels in epithelial ovarian carcinoma. Methods Enzyme-linked hnmunosorbent Assay (ELISA) technique was applied to detect serum HFA levels in healthy women and patients of benign ovarian tumor, borderline ovarian tumor,ovarian carcinoma between December 2007 and December 2008 in Second Affiliated Hospital of Hebei Medical University. The diagnostic values of serum HFA levels were analyzed. Results In healthy womeo, benign ovarian tumor, borderline Ovarian tumor and preoperative ovalian carcinoma, the sermn HE4 median levels were 41. 10, 43.98, 65.21, 260. 90 pmol/L respectively. The HFA levels in the preoperative ovarian carcinoma group were significantly higher than others (P 〈 0. 05). However, there is no significant difference among the healthy women, benign ovarian tumor and borderline ovarian tumor group (P 〉 0.05 ). In ovarian carcinoma group, the median postoperative HFA level was 124. 32 pmol/L, which was significantly lower than preoperative (P 〈0. 05). In ovarian carcinoma group, the preoperative serum HFA levels was related to pathological types and the concentration of CA125. When ovarian carcinoma group was compared with healthy women and benign tumor groups, the HE4 assay in receiver operating characteristic-area under the curve (ROC-AUC) was 0. 960 and the diagnostic specificity was the best when the HE4 assay at the level of 107. 15pmol/L. When HFA set point of 107. 15pmol/L or 15015mol/L,the diagnostic sensitivity was no statistically difference compared with HFA and CA125 test alone. The combined assay of HFA + CA125 was better than CA125 test alone, while HFA single test sensitivity is no less than the combined assay. Conclusion Serum HFA levels could be regarded as a biomarker of the ovarian carcinomas, which could improve the diagnostic rates of ovarian carcinomas when combined with CA125.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2010年第9期684-686,共3页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 卵巢肿瘤 人附睾蛋白4 癌胚抗原125 ovarian tumor human epididymis protein 4 ( HFA ) CA 125
  • 相关文献

参考文献8

  • 1Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HFA expression in normal and malignant human tissues [J]. Mod Pathol, 2006, 19: 847-853.
  • 2Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HFA ( WFD- C2 ) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Res, 2003, 63: 3695-3700.
  • 3Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HFA- (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms[J]. Oncogene, 2002, 21 (17) : 2768-2773.
  • 4Drapkin R, Horsten HH, Lin Y, et al. Human epididymis protein 4 (HFA) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas [ J ]. Cancer Res, 2005, 65 : 2162-2169.
  • 5Osman N, O 'Leary N, Mulcahy E, et al. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre[J]. Ir Med J, 2008, 101(8) : 245 -247.
  • 6Obermair A, Fuller A, Lopez-Varela E, et al. A new progn- ostic model for FIGO stage 1 epithelial ovarian cancer[ J]. Gynecol Oncol, 2007, 104(3): 607-611.
  • 7Moore RG, Mc Meekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HFA and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[ J]. Gynecol Oneol, 2009, 112(1) : 40-46.
  • 8Seholler N, Crawford M, Sato A. Bead-based ELISA for validation of ovarian cancer early detection markers [ J ]. Clin Cancer Res, 2006, 12(7 Pt 1): 2117-2124.

同被引文献185

  • 1李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 2杨蓉,冯捷,房祥忠,白符,成夜霞,刘晨,朱炜,李林.浆液性卵巢癌预后评分模型的建立和预后相关基因的筛选[J].中国妇产科临床杂志,2007,8(4):277-281. 被引量:5
  • 3Penny F Whiting,Marie E Weswood,Anne WS Rutjes,Johannes B Reitsma,Patrick NM Bossuyt,Jos Kleijnen,马章淳,钱楠.QUADAS评价:一种用于诊断性研究的质量评价工具(修订版)[J].中国循证医学杂志,2007,7(7):531-536. 被引量:64
  • 4Andersen MR,Goff BA,Lowe KA,et al.Use of a Symptom Index,CA125,and HE4 to predict ovarian cancer[J].Gynecol Oncol,2010,116(3):378-383.
  • 5Drapkin R,von HHH,Lin Y,et al.Human epididymis protein 4 (HE4) is a secreted glycoprotcin that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res,2005,65(6):2162-2169.
  • 6Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDG2) protein is a biomarker for ovarian cardnoma[J].Cancer Res,2003,63(13):3695-3700.
  • 7Van Gorp T,Gadron I,Despierre E,et al.HE4 and CA125 as a diagnostic test in ovarian cancer:prospective validation of the Risk of Ovarian Malignancy Algorithm[J].Br J Cancer,2011,104(5):863-870.
  • 8Jacob F,Meier M,Caduff R,et al.No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J].Gynecol Oncol,2011,121(3):487-491.
  • 9Shah CA,Lowe KA,Paley P,et al.Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers meso thelin,HE4,and CA125[J].Cancer Epidemiol Biomarkers Prev,2009,18(5):1365-1372.
  • 10Nolen B,Velikokhatnaya L,Marrangoni A,et al.Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass[J].Gynecol Oncol,2010,117(3):440-445.

引证文献17

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部